AstraZeneca’s Tagrisso lung cancer drug will be the first to be paid for by the new-look Cancer Drugs Fund (CDF). In final draft guidance, NICE said Tagrisso (osimertinib) should be funded by ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace AstraZeneca’s Tagrisso as the new standard of care in first-line EGFR ...

Roche's Tarceva and AstraZeneca's own Iressa are the current standard of care in first line treatments of patients with locally advanced or metastatic EGFR+ lung cancer, but Tagrisso looks set to ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso (osimertinib) for approval in the European Union (EU) to treat ...

AstraZeneca AZN will report its first-quarter 2025 earnings on April 29, before market open. The Zacks Consensus Estimate for ...

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as monotherapy and as the backbone for novel ...

Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...

AstraZeneca is scheduled to report results for the first quarter on Tuesday. Here is what you need to know.

Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate ... longer than those who received Astra’s Tagrisso, according to detailed data from a head-to-head study ...

AstraZeneca achieved record revenue growth of 18% in 2024, driven by key products like Farxiga and Tagrisso, and numerous regulatory approvals. The company’s diversified portfolio spans oncology ...